Higher showed no clear difference in asthma ‐ infant incidence compared with lower PUFA intake (low certainty).
It is very uncertain whether higher changes dermatitis/eczema ‐ infant incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes allergic rhinitis ‐ infant incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes food allergy ‐ infant incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes all allergic disease ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes asthma ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes dermatitis/eczema ‐ childhood incidence compared with lower PUFA intake (very low certainty).
It is very uncertain whether higher changes food allergy ‐ childhood incidence compared with lower PUFA intake (very low certainty).
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in Schirmer test (aqueous tear production, measured in mm/5… compared with oral omega‐6 PUFAs (low certainty).
Combined oral omega‐3 and omega‐6 PUFAs showed no clear difference in change in tear film stability, measured using tear break‐up time… compared with placebo (moderate certainty).
Combined oral omega‐3 and omega‐6 PUFAs showed no clear difference in schirmer test (aqueous tear production, measured in mm/5 min, with… compared with placebo (moderate certainty).
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in Schirmer test (aqueous tear production, measured in mm/5… compared with placebo or no treatment (moderate certainty).